HMGA1 augments palbociclib efficacy via PI3K/mTOR signaling in intrahepatic cholangiocarcinoma
Abstract Background Intrahepatic cholangiocarcinoma (iCCA) is a highly aggressive cancer that is challenging to diagnose at an early stage. Despite recent advances in combination chemotherapy, drug resistance limits the therapeutic value of this regimen. iCCA reportedly harbors high HMGA1 expression...
Main Authors: | Zhipeng Li, Huaxin Zhou, Zhijia Xia, Tong Xia, Gang Du, Strohmer Dorothee Franziska, Xiaoming Li, Xiangyu Zhai, Bin Jin |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2023-03-01
|
Series: | Biomarker Research |
Subjects: | |
Online Access: | https://doi.org/10.1186/s40364-023-00473-w |
Similar Items
-
Case report: immunotherapy successfully treated brain metastasis in intrahepatic cholangiocarcinoma and literature review
by: Peiyi Xie, et al.
Published: (2022-08-01) -
Liver Transplantation for Intrahepatic Cholangiocarcinoma: What Are New Insights and What Should We Follow?
by: Dawei Sun, et al.
Published: (2022-01-01) -
The Acquired Vulnerability Caused by CDK4/6 Inhibition Promotes Drug Synergism Between Oxaliplatin and Palbociclib in Cholangiocarcinoma
by: Orawan Suppramote, et al.
Published: (2022-05-01) -
A Refractory Case of CDKN2A/B Loss Metastatic Intrahepatic Cholangiocarcinoma Achieving a Partial Response After First-Line Treatment with Palbociclib
by: Fan W, et al.
Published: (2023-01-01) -
Small duct type intrahepatic cholangiocarcinoma with extensive intraductal extension mimics an intraductal tubulopapillary neoplasm
by: Mark Fowler, et al.
Published: (2023-03-01)